3 results about "Neuroglia" patented technology

This application discloses the application of Bcl11a in the preparation of drugs for nerve injury repair, belonging to the field of biomedical technology. The nerve injury is a central nervous system injury. Overexpression of Bcl11a promotes the transdifferentiation of an intermediate state astrocyte in the cerebral cortex into pyramidal neurons. Using Bcl11a as a molecular intervention target, targeting the M1 motor area of ​​the cerebral cortex, overexpression of Bcl11a in astrocyte subset 2 promotes the reprogramming of astrocytes into pyramidal neurons, promoting the repair of central nervous system injury. Using spatial transcriptome sequencing technology and single-cell sequencing technology, the dynamic trajectory between astrocytes and pyramidal cells was depicted, supporting the transformation of an intermediate transitional state astrocyte in the cortex into pyramidal cell subset 3 after spinal cord injury, indicating that Bcl11a and Zmart4 are key transcription factors in the connection between pyramidal cells and glial cells.

The application discloses a bifidobacterium longum capable of significantly improving 5-HT4R repair of intestinal nerves and an application thereof, and belongs to the field of microorganisms. The bifidobacterium longum CCFM1391 provided by the application can significantly increase the number of intestinal nerve glial cells and intestinal neurons, especially can increase the content of 5-HT, promote the expression of 5-HT4R, promote the secretion of neurotrophic factors, and repair the damaged intestinal nervous system of mice. At the same time, the inflammation reaction of intestinal tissues is relieved, the intestinal immune balance is regulated, and the water reabsorption capacity of the intestinal tract is improved. Therefore, a more personalized treatment scheme can be adopted for gastrointestinal diseases caused by abnormal intestinal nervous system and intestinal motility, and the application prospect is considerable.

This invention, entitled "Temperature- and pH-Sensitive BPA-Targeted Chitosan–Poly(N-isopropylacrylamide)–FPBA Core-Shell Polymeric Nanoparticles Capable of Forming COF Structures in the BNCT Therapeutic Method," pertains to an anti-cancer pharmaceutical composition utilizing novel drug delivery methods. The application of the novel BNCT method is advantageous for cancers such as glioblastoma due to the challenge of crossing the blood-brain barrier. BNCT is a dual and targeted method wherein cancer cells, following the accumulation of ¹⁰B, are irradiated with thermal neutrons. Loading boron-containing compounds into nanoparticles can deliver a high concentration of boron to human glioblastoma cells. Temperature- and pH-sensitive nanoparticles of succinylated chitosan–poly(N-isopropylacrylamide) targeted with BPA are our concept for achieving endocytosis via sialic acid receptors on the surface of glial cells and for the targeted delivery of boron to these cells. By designing temperature- and pH-sensitive, BPA-targeted Chitosan–Poly(N-isopropylacrylamide)–FPBA core-shell polymeric nanoparticles with the capability of forming COF structures in order to simultaneously deliver BPA and FPBA, we aim to utilize the polymeric boron content to perform treatment via the BNCT method. Consequently, damage to healthy cells is reduced to a minimum, and even to zero.